NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the Company's announcement of topline results from its Phase 3 INFRONT-3 trial, evaluating latozinemab in individuals with frontotemporal dementia due to a gene mutation (FTD-GRN). Investors with concerns about Alec's biotech operations may click here for more information.

On October 21, 2025, Alec reported the study results for its Phase 3 INFRONT-3 trial. The study failed to achieve its clinical co-primary endpoint of slowing progression in frontotemporal dementia.

The Company announced topline results from the 96-week double-blind period of its Phase 3 INFRONT-3 trial evaluating latozinemab in slowing disease progression in patients with frontotemporal dementia due to a progranulin gene mutation. The double-blind, randomized trial enrolled 119 patients, including 103 symptomatic individuals with FTD-GRN and 16 at-risk carriers for FTD-GRN aged 37 to 85 years old, with a mean age baseline of 62.1 years.

The INFRONT-3 Phase 3 trial had two co-primary endpoints: biomarker response, which was met, and clinical response, which was not met. Specifically, the trial failed to achieve its efficacy based co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes.

Analysts noted disappointment following the release of the Company's mixed topline results and as a result, downgraded the stock.

Those with questions about Alec's operational performance may contact the firm for a confidential discussion.

Levi & Korsinsky maintains a national securities practice with offices in New York, California, Connecticut, and D.C. Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Joseph E. Levi, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
33 Whitehall Street, 27th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-levi--korsinsky-is-investigating-alec-stock-after-its-phase-3-infront-3-clinical-trial-misses-co-primary-endpoint-302674463.html

SOURCE Levi & Korsinsky, LLP